Usana Health Sciences INC Form 4 insider transactions

Director Ding Xia reports acquiring 4,230 restricted stock units in USANA Health Sciences, vesting quarterly starting July 2025.

Director Timothy E. Wood of USANA Health Sciences acquired 4,230 restricted stock units on May 20, 2025, according to a Form 4 filing with the SEC.

Director Peggie Pelosi reports acquisition of restricted stock units in USANA Health Sciences, signaling potential future ownership.

J Scott Nixon, a director at USANA Health Sciences, reported the acquisition of 4,230 restricted stock units on May 20, 2025, according to a Form 4 filing with the SEC.

John Turman Fleming, a director at USANA Health Sciences, acquired 4,230 restricted stock units on May 20, 2025, according to a Form 4 filing.

Frederic J. Winssinger, a director of USANA Health Sciences, acquired 4,230 restricted stock units on May 20, 2025, according to a Form 4 filing with the SEC.

Director Gilbert A. Fuller of USANA Health Sciences acquired 4,230 restricted stock units on May 20, 2025, according to a Form 4 filing with the SEC.

USANA Health Sciences CFO, G. Doug Iiekkings, sold 4,548 shares of common stock on May 9, 2025.

Director Timothy Wood reports the vesting of restricted stock units and subsequent tax withholding.

Director Frederic J Winssinger executed a transaction involving restricted stock units of USANA Health Sciences, according to a recent SEC Form 4 filing.

Director J Scott Nixon reports a transaction involving restricted stock units of USANA Health Sciences.

Director Peggie Pelosi reports the vesting and disposal of restricted stock units in USANA Health Sciences Inc.

Dr. Myron W. Wentz, a director and 10% owner of USANA Health Sciences, reports a gift of 188,000 shares of common stock.

Director Gilbert A. Fuller reports transactions involving USANA Health Sciences Inc. stock, including the disposition of shares and restricted stock units.

Director John Turman Fleming reports a transaction involving USANA Health Sciences Inc. stock.

Director Ding Xia of USANA Health Sciences reports the vesting and disposal of restricted stock units.

Chief Legal Officer Joshua Foukas of USANA Health Sciences Inc. reports the sale of 5,732 shares of common stock at an average price of $32.539 per share.

Brent Neidig, Chief Commercial Officer of USANA Health Sciences, sold 4,743 shares of common stock at an average price of $32.3397 on March 12, 2025.

Director John Turman Fleming sold 500 shares of USANA Health Sciences Inc. on March 11, 2025, at a price of $33.2954 per share.

David Mulham, Chief Sales Officer of USANA Health Sciences, reports the sale of 3,234 shares of common stock at an average price of $32.9839 on March 10, 2025.

Director Gilbert A Fuller sold 674 shares of USANA Health Sciences Inc. on March 6, 2025, at a price of $31.4398 per share.

USANA Health Sciences CEO Jim Brown sold 5,000 shares of common stock at a price of $29.47 on March 3, 2025.

Kathryn Michelle Armstrong, Chief Scientific Officer of USANA Health Sciences, was granted 16,760 restricted stock units on February 27, 2025, according to a Form 4 filing.

Peter Benedict, Chief Information Officer of USANA Health Sciences, reports the acquisition of 15,625 restricted stock units.

Walter Noot, Chief Operating Officer of USANA Health Sciences Inc., reports the acquisition of 29,687 restricted stock units on February 27, 2025.

Chief Commercial Officer Neidig Brent reports acquiring 26,986 restricted stock units in USANA Health Sciences, vesting over four years.

David Mulham, Chief Sales Officer of USANA Health Sciences, reports the acquisition of 18,641 restricted stock units.

Paul A. Jones, Chief People Officer of USANA Health Sciences, reports the acquisition of 18,385 restricted stock units on February 27, 2025.

G. Doug Iiekking, CFO of USANA Health Sciences, was granted 29,877 restricted stock units on February 27, 2025, according to a Form 4 filing.

Kevin Guest, Executive Chairman of USANA Health Sciences, reports the acquisition of 31,425 restricted stock units on February 27, 2025.